Zenrelia logo

Reach for Zen.

Reach for Zenrelia.

Zenrelia is the NEW treatment for canine allergic itch and inflammation that provides fast and effective relief with just once-daily dosing from the very start1.

Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Gets dogs back to normal

Zenrelia dog

Works fast

Visible improvements in allergic itch from day one²

Zenrelia dog

Optimized dosing

• No loading or tapering, just once a day from the start

• Minimizes opportunity for rebound of itch¹

Zenrelia dog

Continuous efficacy

• Continues to relieve itch and inflammation over the long term¹

• Reduces lesions and inflammation, improving skin condition²

• In clinical field trials, the majority of Zenrelia-treated dogs achieved normal levels of pruritus (PVAS<2)

Safety

Read the entire package insert before using this drug, including the Boxed Warning. 

In clinical trials, the most observed adverse events were vomiting, diarrhea and lethargy.

Tales of Zen

Discover real-life examples of dogs who have benefitted from Zenrelia

Sources of Zen

Dosing Card

Dosing Card

Use this dosing card as a quick reference to help choose the right dose for your patients when prescribing Zenrelia.

Zenrelia Pet Owner Brochure and Itch Tracker

Product Brochure and Itch Tracker

Share this brochure with your clients and encourage them to use the itch tracker to monitor their dog's progress.

INDICATIONS   

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.


IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning.

For full prescribing information call 1-888-545-5973 or visit http://www.elancolabels.com/us/zenrelia

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

About Elanco

Learn why we're a leading provider of innovative solutions that protect and enhance animal health.

Connect with Elanco

Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-0673(3)

© 2024 Elanco or its affiliates.